Cancer-associated thrombosis.
Venous thromboembolic events are common in patients with malignancy, producing both morbidity and mortality. Although the underlying mechanisms by which cancer might promote a procoagulant state are multifaceted and incompletely understood, recent translational research has significantly advanced our understanding of the relationship between cancer and thrombosis. The occurrence of a thromboembolic event in a patient with an active malignancy should be regarded as a life-threatening complication, and decisions regarding prevention and treatment are usually complex. Outcomes may be improved by an evidence-based approach to management with consideration of practice guidelines.
Winters
John
J
Department of Internal Medicine, University of New Mexico School of Medicine, University of New Mexico, Albuquerque, NM 87131, USA.
Garcia
David
D
D000925:Anticoagulants / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D009369:Neoplasms / Q000150:complications* / Q000628:therapy; D013927:Thrombosis / Q000209:etiology* / Q000517:prevention & control*; D054556:Venous Thromboembolism / Q000209:etiology* / Q000517:prevention & control*
D000925:Anticoagulants